Clinical trials
Focal Seizure clinical trials
Below are recruiting focal seizure clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07594119RecruitingPhase 3
Testing RAP-219 to reduce seizures in focal epilepsy
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
Huntsville, AlabamaAges 18–75 - NCT07563881RecruitingPhase 3
Testing RAP-219 for Focal Seizure Control in Adults
This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.
Palmdale, CaliforniaAges 18–75 - NCT07219407RecruitingPhase 2
Long-term safety study of RAP-219 for focal seizures
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
Boise, IdahoAges 18–70 - NCT07233239RecruitingPhase 1
CBD liquid for focal epilepsy seizures
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
Phoenix, ArizonaAges 12–75 - NCT07141329RecruitingPhase 2
Long-term study of SPN-817 for focal seizures
This study gives SPN-817 to people who completed a prior study of the same drug, to see if it stays safe and works well over a longer time. You may qualify if you already finished that study and have stable seizure medicine.
Port Charlotte, FloridaAges 18 years+ - NCT06798896RecruitingPhase 2
SPN-817 for hard-to-control focal seizures
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
Phoenix, ArizonaAges 18–70 - NCT07793396Recruiting
Eslicarbazepine study for adults with partial-onset seizures
This study tests a medication called eslicarbazepine for adults who have partial-onset seizures. It may help people who are newly diagnosed or who have not had good results with two common seizure medicines, carbamazepine or oxcarbazepine.
Lahore, Punjab ProvinceAges 18 years+ - NCT06388707RecruitingPhase 1/Phase 2
Ultrasound therapy for drug-resistant temporal lobe epilepsy
This study tests if a new, non-invasive ultrasound treatment can safely reduce seizures in people whose seizures start in the temporal lobe and have not been controlled by at least two anti-epileptic drugs. The ultrasound is delivered through the scalp to gently stimulate the brain area where the seizures begin.
Palo Alto, CaliforniaAges 18 years+ - NCT05716100RecruitingPhase 3
Study drug for focal epilepsy that isn’t controlled on current meds
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
Little Rock, ArkansasAges 18 years+ - NCT06908356RecruitingPhase 2
Testing PRAX-628 for focal or tonic-clonic seizures
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
Phoenix, ArizonaAges 18–75 - NCT07287163Enrolling by invitationPhase 3
Long-term study of vormatrigine for epilepsy
This trial is for adults with epilepsy who have already taken vormatrigine in a previous study or through a special access program. It aims to collect ongoing safety and effectiveness information.
Miami, FloridaAges 18–85 - NCT07012148RecruitingEarly Phase 1
Seizure forecasting device for temporal lobe epilepsy
This study tests a small device placed under the scalp that may help predict when seizures are likely to happen, using EEG (brain wave) readings. It is designed for people with temporal lobe epilepsy to improve seizure management and safety.
Scottsdale, ArizonaAges 18–75 - NCT06388161Recruiting
Autoantibody study in new focal seizures
This research study looks for specific immune system markers (autoantibodies) in the blood and spinal fluid of people who have recently started having focal seizures (seizures that start in one part of the brain) with no known cause. Finding these markers could help doctors understand why the seizures started.
Hangzhou, ZhejiangAges 14–100 - NCT06492720Recruiting
Testing focused ultrasound for drug-resistant epilepsy
This study tests a new device called NaviFUS that uses focused sound waves to gently stimulate a small area of the brain. It is for people whose seizures start in one part of the brain and are not fully controlled by seizure medicines.
TaipeiAges 18–65 - NCT06466681Recruiting
Attention changes after a seizure in epilepsy
This study looks at how attention and concentration change right after a seizure in people with epilepsy. It uses a short hospital stay to track these changes, which may help improve understanding and future treatment.
LilleAges 18–80 - NCT06922175Recruiting
Study on cenobamate and healthcare use in epilepsy
This study looks at how cenobamate (a medication for seizures) affects healthcare use, like hospital visits or emergency room trips, in people with epilepsy whose seizures were not well-controlled by 2 to 5 other medicines. It is a real-world study, meaning it uses medical records to understand the impact.
Freiburg im Breisgau, GermanyAges 18 years+ - NCT07318870RecruitingPhase 2
Probenecid for reducing seizure clusters during hospital epilepsy monitoring
This trial tests whether a drug called probenecid can help reduce the number of seizures that happen in a cluster during a hospital stay when your seizure medications are being reduced to record your seizures. The goal is to see if giving probenecid can make the monitoring period safer and more effective for people with focal epilepsy being evaluated for surgery.
ParisAges 6–50 - NCT05718817Enrolling by invitationPhase 3
Long-term study of XEN1101 for people with epilepsy
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
Phoenix, ArizonaAges 12 years+
Hear when a new Focal Seizure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Focal Seizure trials by city
Studies with a site in or near these metro areas.
Focal Seizure trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for focal seizure?
- Yes. Clin2 currently lists 18 recruiting focal seizure studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a focal seizure trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a focal seizure trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.